Activity of erlotinib when dosed below maximum tolerable dose for EGFR-mutant lung cancer: implications for targeted therapy development

Eitemau Tebyg

• Delay of treatment change following objective progression on first-line erlotinib in EGFR-mutant lung cancer
  gan: Lo, Peter C., et al.
  Cyhoeddwyd: (2015)
• Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions
  gan: Oxnard, Geoffrey R., et al.
  Cyhoeddwyd: (2013)
• Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib
  gan: Nishino, Mizuki, et al.
  Cyhoeddwyd: (2016)
• Tumor Volume Decrease at 8 weeks is Associated with Longer Survival in EGFR-mutant Advanced Non-Small-Cell Lung Cancer Patients treated with EGFR Tyrosine Kinase Inhibitor
  gan: Nishino, Mizuki, et al.
  Cyhoeddwyd: (2013)
• Management of acquired resistance to EGFR kinase inhibitors in advanced NSCLC
  gan: Sacher, Adrian G., et al.
  Cyhoeddwyd: (2014)